Documentation of Humira in Psoriasis Patients in Routine Clinical Practice

Brief description of study

Safety and Effectiveness of adalimumab (Humira) in Psoriasis Patients in Routine Clinical
Practice.

Detailed Study Description

Postmarketing Observational Study to Evaluate the Work Productivity, Safety and Efficacy of
Humira for the Treatment of Moderate to Severe Plaque Psoriasis in Daily Clinical Practice.
The primary objectives of the PMOS are to explore changes in health related care utilization
data by the evaluation of:

the number of missed working days

the number of visits to doctor's office

the number and duration of hospitalizations

work ability to assess efficacy for different subgroups by

the number of patients achieving a PASI 75 response to evaluate safety by

the documentation and analysis of adverse events for all patients and subgroups with
concomitant diseases Secondary objectives include the exploration of changes in quality
of life measurements, of the influence of age, gender and duration of disease